• Dr. Carrillo-Larco's Presentation Slides (PDF)

During his lecture, Dr. Carrillo-Larco describes selected features of cardiometabolic epidemiology for Hispanics, global and international comparisons, as well as recent advances and opportunities for risk-based prevention of noncommunicable diseases. Hispanics in the U.S. represent the second largest racial or ethnic group (~18% of the total U.S. population in 2020). This important ethnic group has unique health experiences including migration and health disparities as well as remarkable epidemiological features such as high diabetes-related mortality. Furthermore, in comparison to other world regions, Latin America exhibits great diversity in the distribution of modifiable cardiometabolic risk factors — for instance, low HDL-cholesterol is the most common dyslipidemia in this world region. Despite these unique traits, tools for risk stratification and disease prevention specific for cardiometabolic noncommunicable diseases are limited for this ethnic group. 

Rodrigo M. Carrillo-Larco, M.D., Ph.D., was born and raised in Lima, Peru and completed his medical training at Universidad Peruana Cayetano Heredia (Lima, Peru). Shortly after, he moved to London, U.K., where he worked as a Global Health Research Fellow and received his Ph.D. from the Department of Epidemiology and Biostatistics at Imperial College London. Dr. Carrillo-Larco set up the Cohorts Consortium of Latin America and the Caribbean, a collaboration to develop the first tool for risk stratification and primary prevention of cardiovascular diseases in Latin America. Dr. Carrillo-Larco has authored 120+ academic publications. Dr. Carrillo-Larco’s research seeks to bring (big) data sources non-traditionally used in epidemiological and public health research, together with novel analytical approaches, to provide timely and pragmatic evidence as well as tools to solve problems in global health. Most of Dr. Carrillo-Larco’s work has been about primary prevention of noncommunicable diseases, particularly cardiovascular diseases and diabetes.